Resmetirom, sold under the brand name Rezdiffra, is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis. It is a thyroid hormone receptor beta agonist.
The most common side effects include diarrhea and nausea.
Resmetirom was approved for medical use in the United States in March 2024. The US Food and Drug Administration considers it to be a first-in-class medication. From Wikipedia
